These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15206108)

  • 1. Antitumor titanium compounds and related metallocenes.
    Caruso F; Rossi M
    Met Ions Biol Syst; 2004; 42():353-84. PubMed ID: 15206108
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruthenium anticancer drugs.
    Alessio E; Mestroni G; Bergamo A; Sava G
    Met Ions Biol Syst; 2004; 42():323-51. PubMed ID: 15206107
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
    Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
    Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-based neutral ruthenium(II) arene complex: selective anticancer action.
    Wu CH; Wu DH; Liu X; Guoyiqibayi G; Guo DD; Lv G; Wang XM; Yan H; Jiang H; Lu ZH
    Inorg Chem; 2009 Mar; 48(6):2352-4. PubMed ID: 19220049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
    Peacock AF; Sadler PJ
    Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
    Bergamo A; Sava G
    Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly selective apoptotic cell death induced by halo-salane titanium complexes.
    Immel TA; Debiak M; Groth U; Bürkle A; Huhn T
    ChemMedChem; 2009 May; 4(5):738-41. PubMed ID: 19343766
    [No Abstract]   [Full Text] [Related]  

  • 9. Metal complexes as therapeutic agents in nitrogen monoxide modulation.
    Fricker SP
    Met Ions Biol Syst; 2004; 41():421-80. PubMed ID: 15206124
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and anticancer activity of certain mononuclear Ru (II) complexes.
    Rathinasamy S; Karki SS; Bhattacharya S; Manikandan L; Prabakaran SG; Gupta M; Mazumder UK
    J Enzyme Inhib Med Chem; 2006 Oct; 21(5):501-7. PubMed ID: 17194018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonyl-substituted titanocenes: a novel class of cytostatic compounds with high antitumor and antileukemic activity.
    Gansäuer A; Winkler I; Worgull D; Lauterbach T; Franke D; Selig A; Wagner L; Prokop A
    Chemistry; 2008; 14(14):4160-3. PubMed ID: 18384037
    [No Abstract]   [Full Text] [Related]  

  • 12. Gold complexes as antitumor agents.
    Messori L; Marcon G
    Met Ions Biol Syst; 2004; 42():385-424. PubMed ID: 15206109
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis, characterization, in vitro antitumor activity, DNA-binding properties and electronic structure (DFT) of the new complex cis-(Cl,Cl)[RuIICl2(NO+)(terpy)]Cl.
    Karidi K; Garoufis A; Tsipis A; Hadjiliadis N; den Dulk H; Reedijk J
    Dalton Trans; 2005 Apr; (7):1176-87. PubMed ID: 15782252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanics aided design of antineoplastic agents from ruthenium coordinate complexes.
    Mazumder UK; Gupta M; Mukherjee A; Mukhopadhyay DK; Dey P
    Indian J Exp Biol; 1999 Jul; 37(7):667-70. PubMed ID: 10522155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer activity of cyclic amine and thiaether metal complexes.
    Medvetz DA; Stakleff KD; Schreiber T; Custer PD; Hindi K; Panzner MJ; Blanco DD; Taschner MJ; Tessier CA; Youngs WJ
    J Med Chem; 2007 Apr; 50(7):1703-6. PubMed ID: 17343369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.
    Karki SS; Thota S; Darj SY; Balzarini J; De Clercq E
    Bioorg Med Chem; 2007 Nov; 15(21):6632-41. PubMed ID: 17765549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active cytotoxic reagents based on non-metallocene non-diketonato well-defined C2-symmetrical titanium complexes of tetradentate bis(phenolato) ligands.
    Shavit M; Peri D; Manna CM; Alexander JS; Tshuva EY
    J Am Chem Soc; 2007 Oct; 129(40):12098-9. PubMed ID: 17877357
    [No Abstract]   [Full Text] [Related]  

  • 20. Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines.
    Pascu GI; Hotze AC; Sanchez-Cano C; Kariuki BM; Hannon MJ
    Angew Chem Int Ed Engl; 2007; 46(23):4374-8. PubMed ID: 17477461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.